Showing results (91-100 of 118) with videos related to

Sort By:
Pageof 12
Lancet (London, England)|August 16, 2015
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trialMiklos Pless, Roger Stupp, Hans-Beat Ris, et al.
International Journal of Cancer|August 26, 2016
Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivoTali Voloshin, Mijal Munster, Roni Blatt, et al.
Cancers|June 24, 2022
Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In VivoShiri Davidi, Sara Jacobovitch, Anna Shteingauz, et al.
Cancers|February 25, 2023
Correction: Davidi et al. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo. Cancers 2022, 14, 2959Shiri Davidi, Sara Jacobovitch, Anna Shteingauz, et al.
The Lancet. Oncology|September 1, 2023
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 studyTiciana Leal, Rupesh Kotecha, Rodryg Ramlau, et al.
Frontiers in Oncology|July 12, 2024
Tumor Treating Fields (TTFields) induce homologous recombination deficiency in ovarian cancer cells, thus mitigating drug resistanceYani Berckmans, Hila M Ene, Kerem Ben-Meir, et al.
Frontiers in Oncology|March 25, 2026
Tumor Treating Fields (TTFields), and their concomitant application with FOLFOX, are effective for the treatment of gastric cancer cellsHila Fishman, Hila M Ene, Einav Zeevi, et al.
Frontiers in Immunology|July 16, 2026
Extracellular vesicles as prognostic biomarkers: results of a neoadjuvant chemoimmunotherapy clinical trial in stage IIIA (N2) non-small-cell lung cancer (SAKK 16/14)Yannik da Silva, Dapi Menglin Chiang, Laura Benecke, et al.
International Journal of Molecular Sciences|November 26, 2022
Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo ModelYiftah Barsheshet, Tali Voloshin, Boris Brant, et al.
Molecular Cancer Therapeutics|June 30, 2025
Cancer Cell Permeability Induced by Tumor Treating Fields (TTFields) as a Physical Approach to Improve Chemotherapy Uptake and Overcome Multidrug ResistanceBella Koltun, Tali Voloshin, Cfir David, et al.
Pageof 12